SciBX: Science-Business eXchange Contents: October 23 2014, Volume 7 / Issue 41

If you are unable to see the message below, click here to view.

Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Telormedix   TABLE OF CONTENTS October 23 2014, Volume 7 / Issue 41 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Endocrine/metabolic disease Infectious disease Inflammation The Distillery: Techniques Assays and screens Disease models Drug delivery Drug platforms Imaging Markers Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The September 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with TheraMAB   Analysis Cover Story Top Diagnosing resistance Lauren Martz doi:10.1038/scibx.2014.1196 The frontier for combating antibiotic resistance is now in developing fast, sensitive and versatile diagnostics that can improve treatment and optimize clinical trials. Full Text | PDF Targets and Mechanisms Top Branching out in pancreatic cancer Benjamin Boettner doi:10.1038/scibx.2014.1197 Changes in circulating levels of branched-chain amino acids detectable 2–5 years before the onset of pancreatic cancer could lead to diagnostic markers for the indication. Full Text | PDF Tools Top Programmable sensitivity Stephen Parmley doi:10.1038/scibx.2014.1198 CRISPR-based antimicrobials can resensitize antibiotic-resistant bacteria by targeting specific resistance genes and could add new tools for combating resistance. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Matrix metalloproteinase 13 (MMP13) doi:10.1038/scibx.2014.1199 In vitro and rat studies identified selective MMP13 inhibitors that could be useful for treating osteoarthritis. Full Text | PDF Cancer Top Spermidine/spermine-N1-acetyltransferase 1 (SAT1; SSAT) doi:10.1038/scibx.2014.1200 Studies in patients, mice and cell culture suggest inhibiting SAT1 could help overcome resistance to radiotherapy in glioblastoma multiforme (GBM). Full Text | PDF AT rich interactive domain 1A (ARID1A); ARID1B; breast cancer 1 early onset (BRCA1); BRCA2; K-Ras (KRAS); phosphoinositide 3-kinase (PI3K) doi:10.1038/scibx.2014.1201 Genetic studies identified mutations in chromatin-remodeling genes that could be corrected to help treat carcinosarcomas. Full Text | PDF Dermcidin (DCD) doi:10.1038/scibx.2014.1202 Cell culture studies suggest the Serinicoccus-derived natural compound seriniquinone could help treat cancer. Full Text | PDF Protein disulfide isomerase (PDI) doi:10.1038/scibx.2014.1203 Cell culture studies suggest PDI inhibitors could sensitize cancers to etoposide chemotherapy. Full Text | PDF Lymphotoxin-α (LTα); lymphotoxin-β receptor (LTBR); chemokine CXC motif ligand 13 (CXCL13); CXC chemokine receptor 5 (CXCR5) doi:10.1038/scibx.2014.1204 Mouse studies suggesting inhibiting LTα-LTBR signaling or CXCL13-CXCR5 signaling could help treat CLL. Full Text | PDF l-2-hydroxyglutarate dehydrogenase (L2HGDH) doi:10.1038/scibx.2014.1205 In vitro studies suggest agonizing L2HGDH could help treat renal cell carcinoma (RCC). Full Text | PDF Casein kinase 1 (CSNK1; CKI) doi:10.1038/scibx.2014.1206 In vitro and mouse studies suggest inhibiting CSNK1 could help treat MDS. Full Text | PDF Endocrine/metabolic disease Top Not applicable doi:10.1038/scibx.2014.1207 Mouse and in vitro studies suggest an ethanolamine salt of the antihelminthic drug niclosamide could be useful for treating type 2 diabetes. Full Text | PDF G protein–coupled receptor 119 (GPR119) doi:10.1038/scibx.2014.1208 In vitro and mouse studies suggest gordonoside F could help treat obesity and diabetes. Full Text | PDF Neurokinin 3 receptor (TACR3; NK3R); gonadotropin-releasing hormone (GnRH) doi:10.1038/scibx.2014.1209 In vitro and goat studies identified peptidomimetic NK3R agonists that could help treat infertility. Full Text | PDF Infectious disease Top Interleukin-1β (IL-1β) doi:10.1038/scibx.2014.1210 Mouse studies suggest altering the composition of the intestinal microbiome could help prevent osteomyelitis (bone infection). Full Text | PDF Inflammation Top Transient receptor potential vanilloid 1 (TRPV1; VR1) doi:10.1038/scibx.2014.1211 In vitro and mouse studies suggest antagonizing TRPV1 could decrease inflammation in colitis and inflammatory bowel disease (IBD). Full Text | PDF Distillery: Techniques Assays and screens Top Label-free electrochemical detection of methyltransferases doi:10.1038/scibx.2014.1212 A label-free electrochemical system for detecting methyltransferases could help distinguish tumor tissue from normal tissue without the use of radioactive or fluorescent probes. Full Text | PDF Disease models Top Genetically defined triple-knockout mouse model of high-grade superficial bladder cancer doi:10.1038/scibx.2014.1213 A triple-knockout mouse model of bladder cancer could be useful for studying disease biology and evaluating new candidate therapies for high-grade superficial bladder cancer. Full Text | PDF Nonhuman primate model of β-amyloid (Aβ)-induced Alzheimer's disease (AD) doi:10.1038/scibx.2014.1214 Nonhuman primates receiving intracerebroventricular injections of Aβ oligomers could be useful as models for evaluating new treatments for AD. Full Text | PDF Drug delivery Top Cytosolic delivery of antibody mimics using anthrax toxin protective antigen (PA) and the N-terminal domain (LFN) of the anthrax toxin lethal factor (LF) doi:10.1038/scibx.2014.1215 Cell culture studies suggest the PA/LFN system could enable cytosolic delivery of small antibody mimics to inhibit intracellular oncoproteins and help treat cancer. Full Text | PDF Hydrogel delivery system for controlled delivery of bupivacaine doi:10.1038/scibx.2014.1216 A hydrogel delivery system could enable controlled delivery of the generic anesthetic bupivacaine with few side effects. Full Text | PDF Drug platforms Top Clustered, regularly interspaced short palindromic repeats (CRISPR)-Cas9 genome editing for designing antibiotic, RNA-guided nucleases doi:10.1038/scibx.2014.1217 Mouse, moth and cell culture studies suggest CRISPR-Cas9 genome editing could be used to develop new treatments against antibiotic-resistant bacterial infections. Full Text | PDF DEP domain containing 6 (DEPTOR; DEPDC6) inhibition to enhance differentiation of embryonic stem (ES) cells doi:10.1038/scibx.2014.1218 Cell culture studies suggest DEPTOR inhibition could help promote in vitro differentiation of ES cells into desired cell types. Full Text | PDF Prevention of immunogenicity to therapeutic proteins by co-treatment with O-phospho-L-serine (OPLS) doi:10.1038/scibx.2014.1219 Cell culture and mouse studies suggest OPLS could prevent immunogenicity against protein therapeutics. Full Text | PDF Imaging Top Dual-modality immuno–single-photon emission computed tomography (immuno-SPECT) and near-infrared fluorescence (NIRF) imaging probes to guide prostate cancer surgery doi:10.1038/scibx.2014.1220 A dual-modality probe called RDC018 that enables imaging with immuno-SPECT and NIRF could help guide surgical resection of prostate tumors. Full Text | PDF Markers Top Seven-antibody composite biomarker panel to predict recurrent focal segmental glomerulosclerosis (rFSGS) after kidney transplantation doi:10.1038/scibx.2014.1221 Studies in human samples suggest a signature of seven pathogenic antibodies could help predict rFSGS after kidney transplantation, which can lead to graft rejection. Full Text | PDF Single-cell immune signatures from mass cytometry to predict clinical recovery from surgery doi:10.1038/scibx.2014.1222 Single-cell immune signatures generated via mass cytometry could help predict recovery outcomes in patients following surgery. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.